Adia Nutrition Inc. Announces IRB Approval from BeyondBound for Adia Med's Autism Clinical Study

About this update from Adia Nutrition, Inc.

[{"type":"text","content":"Winter Park, Florida--(Newsfile Corp. - December 15, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), a leader in regenerative medicine through its Adia Med subsidiary, today announced that the independent Institutional Review Board (IRB) BeyondBound has approved the company's patent-pending clinical study protocol focused on Autism Spectrum Disorder (ASD).","length":357,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","className":"","disableSlideshowImg":false,"size":{"original":{"width":550,"height":412,"url":"https://media.zenfs.com/en/newsfile_64/ed77935a1a1da88def6dba9e38038287"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/szpP63q6DxtcBCZPXRN0dA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTcxOTtjZj13ZWJw/https://media.zenfs.com/en/newsfile_64/ed77935a1a1da88def6dba9e38038287","width":550,"height":412}},"href":"https://images.newsfilecorp.com/files/10520/278050_adia_irb_approved_screenshot.jpg","hrefExternal":true},{"type":"text","content":"IRB Approval Email","length":18,"tagName":"p","attribs":{}},{"type":"text","content":"To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/10520/278050_adia_irb_approved_screenshot.jpg","length":142,"tagName":"p","attribs":{}},{"type":"text","content":"The approved study, titled "Adia Med of Winter Park LLC Autism Spectrum Disorder Research Study", will enroll 100 children ages 3-12 and investigate whether combining glutathione with umbilical cord blood-derived stem cells provides greater therapeutic benefits compared to glutathione alone. Key outcome measures include potential improvements in social interaction, communication, behavior, overall quality of life, and other core areas impacted by ASD.","length":465,"tagName":"p"},{"type":"text","content":"Study details have been submitted to ClinicalTrials.gov and are currently in the final review stage before becoming publicly visible. Adia Nutrition will notify shareholders and interested parties once the listing is live.","length":222,"tagName":"p"},{"type":"text","content":"Patient recruitment is expected to begin in January 2026, with regular updates provided on enrollment and study progress.","length":121,"tagName":"p"},{"type":"text","content":""This approval from BeyondBound is a key milestone in advancing potential new options for individual...

More updates from Adia Nutrition, Inc.